Home LiteratureArticle Details
PMID: 2184009 Published · ppublish English Journal Article Review

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Drugs ·Vol. 39 ·No. 3 ·1990-03-00 ·Pages 438-90

Henwood JM, Brogden RN

Abstract

暂无摘要

MeSH Terms
Animals Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics,therapeutic use Etoposide/administration & dosage,pharmacokinetics Humans Neoplasms/drug therapy
Chemicals
Etoposide
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Henwood J M
ADIS Drug Information Services, Manchester, England.
Brogden R N
References (336)
336 references, click to expand
  1. New combination chemotherapy for relapsed acute myeloid leukaemia.
    Lancet. 1984 Jun 2;1(8388):1232 PMID: 6144937
  2. Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.
    Blood. 1988 Nov;72(5):1567-73 PMID: 3052626
  3. Phase II study of etoposide in the treatment of esophageal carcinoma.
    Cancer Treat Rep. 1983 Apr;67(4):397-8 PMID: 6850656
  4. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
    Eur J Cancer Clin Oncol. 1986 Feb;22(2):173-9 PMID: 3699080
  5. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.
    Cancer Chemother Pharmacol. 1982;7(2-3):231-3 PMID: 6896298
  6. Improvement of long-term survival in extensive small-cell lung cancer.
    J Clin Oncol. 1988 Jul;6(7):1161-9 PMID: 2839632
  7. Etoposide (VP-16-213) in malignant brain tumors: a phase II study.
    J Clin Oncol. 1984 May;2(5):432-7 PMID: 6726296
  8. Possible enhancement of vincristine neuropathy by VP-16.
    Cancer. 1982 Mar 1;49(5):859-64 PMID: 6277454
  9. Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience.
    Cancer Treat Rep. 1986 Nov;70(11):1337-8 PMID: 3768877
  10. Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer.
    Thorax. 1989 Mar;44(3):215-9 PMID: 2539655
  11. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.
    Am J Clin Oncol. 1988 Oct;11(5):566-71 PMID: 2845769
  12. High-dose etoposide in the treatment of relapsed primary brain tumors.
    Cancer Treat Rep. 1985 Jun;69(6):603-5 PMID: 4016766
  13. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
    Cancer Treat Rep. 1976 Sep;60(9):1247-50 PMID: 797447
  14. Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
    Cancer Chemother Pharmacol. 1986;18 Suppl 2:S34-9 PMID: 3028662
  15. A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer.
    Eur J Cancer Clin Oncol. 1989 Jul;25(7):1039-43 PMID: 2547622
  16. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.
    N Engl J Med. 1987 Apr 9;316(15):912-8 PMID: 3029592
  17. Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies.
    Eur J Cancer Clin Oncol. 1987 Nov;23(11):1627-32 PMID: 2828072
  18. Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.
    Br Med J. 1973 Jul 28;3(5873):199-202 PMID: 4578134
  19. Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer.
    Cancer Chemother Pharmacol. 1982;7(2-3):187-93 PMID: 6282482
  20. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.
    Cancer. 1988 Jul 1;62(1):32-5 PMID: 3289726
  21. Etoposide salvage therapy for refractory germ cell tumors: an update.
    Cancer Treat Rev. 1982 Jun;9 Suppl:67-71 PMID: 6290056
  22. Inefficacy of cisplatin and etoposide as salvage therapy for children with recurrent or unresponsive soft tissue sarcoma.
    Cancer Treat Rep. 1987 Apr;71(4):407-8 PMID: 3829015
  23. Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer.
    Gynecol Oncol. 1987 Jun;27(2):233-40 PMID: 3570062
  24. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
    Bone Marrow Transplant. 1987 Oct;2(3):287-98 PMID: 3502785
  25. Chemotherapy of refractory germ cell cancer with Etoposide.
    J Clin Oncol. 1983 Nov;1(11):706-9 PMID: 6321675
  26. In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma.
    Eur J Cancer Clin Oncol. 1982 Apr;18(4):377-80 PMID: 6889515
  27. Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.
    Cancer Res. 1983 Apr;43(4):1568-74 PMID: 6831403
  28. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma.
    Cancer Treat Rep. 1985 May;69(5):483-8 PMID: 2408750
  29. Variable bioavailability following repeated oral doses of etoposide.
    Eur J Cancer Clin Oncol. 1985 Nov;21(11):1315-9 PMID: 3000790
  30. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.
    Eur J Cancer. 1981 Feb;17(2):245-9 PMID: 7262161
  31. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.
    Cancer Treat Rep. 1976 Sep;60(9):1295-1306 PMID: 1016966
  32. Treatment of persistent or relapsing advanced germ cell neoplasms with cisplatin, etoposide and bleomycin.
    Eur J Cancer Clin Oncol. 1986 May;22(5):595-9 PMID: 2429840
  33. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.
    Cancer Chemother Pharmacol. 1989;24(5):329-31 PMID: 2758563
  34. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
    Eur J Cancer. 1976 Mar;12(3):181-8 PMID: 939236
  35. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
    Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73 PMID: 291480
  36. Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia.
    J Clin Oncol. 1985 Jun;3(6):789-92 PMID: 3859585
  37. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung.
    J Clin Oncol. 1987 Sep;5(9):1401-9 PMID: 3040923
  38. Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
    Br J Cancer. 1989 Jul;60(1):98-101 PMID: 2553090
  39. VP-16-213 in combination chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association.
    J Clin Oncol. 1984 Dec;2(12):1343-51 PMID: 6096517
  40. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells.
    Biochemistry. 1976 Dec 14;15(25):5443-8 PMID: 999819
  41. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.
    Cancer Chemother Pharmacol. 1985;15(1):16-9 PMID: 4006044
  42. Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): implications for mode of action.
    Biochem Pharmacol. 1985 Jun 1;34(11):2036-40 PMID: 4004921
  43. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.
    Br J Cancer. 1985 Sep;52(3):363-7 PMID: 2994705
  44. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
    Cancer Clin Trials. 1980;3(4):325-8 PMID: 6933027
  45. Primary oral etoposide therapy in gestational trophoblastic disease. An update.
    Cancer. 1986 Jul 1;58(1):14-7 PMID: 3011237
  46. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
    Ann Intern Med. 1988 Oct 1;109(7):540-6 PMID: 2844110
  47. VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK).
    Semin Oncol. 1985 Mar;12(1 Suppl 2):33-6 PMID: 3975656
  48. High-dose cisplatin and etoposide in advanced malignancies of childhood.
    Pediatr Hematol Oncol. 1987;4(4):329-36 PMID: 3152939
  49. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium).
    Cancer. 1982 Dec 15;50(12):2751-6 PMID: 6890404
  50. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts.
    Cancer Res. 1983 Dec;43(12 Pt 1):5699-706 PMID: 6580063
  51. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
    Chemioterapia. 1986 Apr;5(2):125-7 PMID: 3518965
  52. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
    J Clin Oncol. 1989 Sep;7(9):1295-302 PMID: 2788716
  53. VP-16-213 and cisplatin in the treatment of patients with refractory germ cell tumors.
    Am J Clin Oncol. 1984 Aug;7(4):327-30 PMID: 6331151
  54. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Cancer Treat Rep. 1984 Dec;68(12):1513-4 PMID: 6509456
  55. VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma.
    Cancer. 1985 Sep 1;56(5):1006-13 PMID: 3893681
  56. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.
    Cancer Res. 1986 Apr;46(4 Pt 2):1939-42 PMID: 3004712
  57. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
    Cancer. 1988 Jul 1;62(1):24-7 PMID: 3133101
  58. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
    J Clin Oncol. 1989 Jul;7(7):932-9 PMID: 2544687
  59. Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.
    Cancer Chemother Pharmacol. 1987;19(3):221-5 PMID: 3581415
  60. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
    Cancer Treat Rep. 1987 Jan;71(1):61-6 PMID: 3024828
  61. Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.
    Cancer Chemother Pharmacol. 1983;10(3):208-11 PMID: 6861265
  62. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
    Cancer Res. 1984 Dec;44(12 Pt 1):5857-60 PMID: 6094001
  63. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.
    Cancer Chemother Pharmacol. 1987;19(3):246-9 PMID: 3581418
  64. Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung.
    Cancer Treat Rep. 1985 May;69(5):479-81 PMID: 2988773
  65. High dose etoposide does not cause peripheral neuropathy.
    Cancer Chemother Pharmacol. 1987;19(2):180-1 PMID: 3568278
  66. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.
    Br J Cancer. 1989 Apr;59(4):584-90 PMID: 2540789
  67. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Cancer Treat Rep. 1987 Jun;71(6):639-41 PMID: 3581103
  68. Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma.
    Jpn J Clin Oncol. 1987 Jun;17(2):113-5 PMID: 3039199
  69. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
    Cancer Treat Rep. 1986 Jul;70(7):893-5 PMID: 3719581
  70. VP-16 plus cyclophosphamide in the treatment of advanced lung cancer.
    Cancer. 1983 Feb 1;51(3):385-9 PMID: 6295601
  71. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Cancer Treat Rep. 1981 Jul-Aug;65(7-8):703-4 PMID: 7248987
  72. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cancer Treat Rep. 1978 Mar;62(3):473-5 PMID: 348319
  73. Phase II study of etoposide for carcinoma of the prostate.
    Cancer Treat Rep. 1986 Jun;70(6):771-2 PMID: 3524825
  74. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.
    Cancer Treat Rep. 1986 May;70(5):665-7 PMID: 3708614
  75. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    J Clin Oncol. 1989 Feb;7(2):179-85 PMID: 2644397
  76. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
    Am J Clin Oncol. 1986 Aug;9(4):307-10 PMID: 3529919
  77. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.
    J Clin Oncol. 1988 Jul;6(7):1134-43 PMID: 3292713
  78. Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
    Cancer Treat Rep. 1986 Mar;70(3):339-41 PMID: 3955545
  79. Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract.
    Cancer Treat Rep. 1987 Mar;71(3):329-30 PMID: 3815400
  80. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Cancer Treat Rep. 1985 Mar;69(3):269-73 PMID: 3884152
  81. Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors.
    Cancer Treat Rev. 1982 Jun;9 Suppl:79-84 PMID: 7127338
  82. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
    J Clin Oncol. 1986 Jul;4(7):1089-93 PMID: 3459812
  83. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors.
    Cancer Res. 1987 Jan 1;47(1):119-22 PMID: 3466686
  84. Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.
    Semin Oncol. 1986 Sep;13(3 Suppl 3):40-4 PMID: 3020699
  85. Action of etoposide (VP-16-123) on human cells: no evidence for topoisomerase II involvement in excision repair of u.v.-induced DNA damage, nor for mitochondrial hypersensitivity in ataxia telangiectasia.
    Carcinogenesis. 1987 Nov;8(11):1613-8 PMID: 2822276
  86. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.
    Cancer Treat Rep. 1987 Feb;71(2):201-3 PMID: 3802115
  87. Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer.
    Cancer Treat Rep. 1985 Nov;69(11):1335-6 PMID: 4092199
  88. Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms.
    Cancer Treat Rep. 1985 Mar;69(3):259-61 PMID: 2983893
  89. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    J Clin Oncol. 1989 Sep;7(9):1333-40 PMID: 2549204
  90. A comparison of the mechanisms of action of VP-16-213 and podophyllotoxin.
    Lloydia. 1977 Jan-Feb;40(1):82-9 PMID: 875640
  91. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
    J Clin Oncol. 1988 Aug;6(8):1231-8 PMID: 2457657
  92. Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.
    Med Pediatr Oncol. 1981;9(3):205-8 PMID: 6264280
  93. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
    J Clin Oncol. 1989 Aug;7(8):1087-92 PMID: 2547028
  94. Antimetastasis effect of two derivatives of epiposophyllotoxin in mice.
    Eur J Cancer. 1976 Oct;12(10):797-805 PMID: 976288
  95. Possible benefit of doxorubicin treatment in patients with refractory germ cell cancer.
    Cancer. 1986 Dec 1;58(11):2393-8 PMID: 2429755
  96. CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
    Br J Cancer. 1989 Jul;60(1):79-82 PMID: 2679846
  97. Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.
    J Clin Oncol. 1987 Feb;5(2):185-9 PMID: 3027268
  98. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Cancer Treat Rep. 1982 Aug;66(8):1669-71 PMID: 7105059
  99. Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
    Med Pediatr Oncol. 1986;14(5):245-50 PMID: 2431255
  100. Phase II study of etoposide in previously untreated squamous cell carcinoma of the head and neck.
    Cancer Treat Rep. 1987 Mar;71(3):321-2 PMID: 3815398
  101. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents.
    Cancer Res. 1984 Feb;44(2):626-32 PMID: 6318974
  102. Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung.
    Cancer Treat Rep. 1986 Jul;70(7):891-2 PMID: 3719580
  103. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
    Pharmacotherapy. 1984 Mar-Apr;4(2):61-73 PMID: 6326063
  104. The podophyllotoxin derivatives VP16-213 and VM26.
    Cancer Chemother Pharmacol. 1982;7(2-3):73-80 PMID: 7044593
  105. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.
    J Clin Oncol. 1983 Nov;1(11):701-5 PMID: 6366131
  106. Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.
    Cancer Chemother Pharmacol. 1986;17(1):80-4 PMID: 3698181
  107. VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasms.
    Cancer Chemother Pharmacol. 1982;7(2-3):215-8 PMID: 6282486
  108. Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
    Semin Oncol. 1986 Sep;13(3 Suppl 3):24-30 PMID: 3020695
  109. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.
    Cancer Res. 1983 Apr;43(4):1592-7 PMID: 6572554
  110. Intracarotid VP-16 in malignant brain tumors.
    J Neurooncol. 1987;4(4):397-401 PMID: 3572470
  111. Treatment of chronic myelomonocytic leukemia with low dose etoposide.
    Br J Haematol. 1989 Jul;72(3):468-71 PMID: 2765411
  112. Differential patterns of anti-tumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines.
    Int J Cancer. 1988 Sep 15;42(3):373-81 PMID: 3417366
  113. Improved prognosis for children with stage IV neuroblastoma: high-dose melphalan and autologous unpurged marrow transplantation after aggressive surgery and short chemotherapy with cisplatinum and etoposide.
    Pediatr Hematol Oncol. 1988;5(2):125-35 PMID: 3152958
  114. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
    Cancer Res. 1985 Jul;45(7):3106-12 PMID: 3839166
  115. VP-16-213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: an interim report.
    Cancer Treat Rep. 1981 Nov-Dec;65(11-12):987-93 PMID: 7028260
  116. Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer.
    Cancer. 1987 Nov 15;60(10):2382-7 PMID: 2822217
  117. Podophyllotoxin-resistant mutants of Chinese hamster ovary cells: cross-resistance studies with various microtubule inhibitors and podophyllotoxin analogues.
    Cancer Res. 1983 Feb;43(2):505-12 PMID: 6848174
  118. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
    Tumori. 1985 Oct 31;71(5):499-500 PMID: 4060251
  119. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
    Exp Hematol. 1988 Feb;16(2):97-101 PMID: 3276544
  120. Etoposide prior to cis-diamminedichloroplatinum in combination chemotherapy: in vitro and in vivo studies.
    Eur J Cancer Clin Oncol. 1985 Dec;21(12):1501-6 PMID: 3830728
  121. Etoposide (VP-16-213).
    Cancer Treat Rev. 1979 Jun;6(2):107-24 PMID: 385138
  122. Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts.
    Cancer Res. 1986 Nov;46(11):5641-5 PMID: 3019531
  123. Management of high risk patients with advanced testis cancer: National Cancer Institute approach.
    Semin Oncol. 1988 Aug;15(4):335-8 PMID: 2457255
  124. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer.
    Cancer Treat Rep. 1985 Apr;69(4):369-71 PMID: 2986833
  125. VP-16 and adriamycin in patients with advanced breast cancer.
    Am J Clin Oncol. 1982 Oct;5(5):505-9 PMID: 6897491
  126. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.
    J Clin Oncol. 1987 Apr;5(4):585-91 PMID: 3031225
  127. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Cancer Treat Rep. 1986 Jun;70(6):801-2 PMID: 3524829
  128. Cisplatin plus VP16-213 in refractory ovarian carcinoma.
    Am J Clin Oncol. 1987 Feb;10(1):21-2 PMID: 3825989
  129. Oral etoposide in gestational trophoblastic disease.
    Cancer Treat Rep. 1984 May;68(5):775-7 PMID: 6327035
  130. Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines.
    Cancer Res. 1973 Dec;33(12):3123-9 PMID: 4760528
  131. The clinical pharmacology of VM26 and VP16-213. A brief overview.
    Cancer Chemother Pharmacol. 1982;7(2-3):133-40 PMID: 7044592
  132. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.
    Cancer. 1974 Oct;34(4):985-92 PMID: 4608026
  133. Etoposide single-agent chemotherapy for solid tumors.
    Cancer Treat Rev. 1982 Jun;9 Suppl:31-7 PMID: 6290055
  134. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
    J Clin Oncol. 1986 Jan;4(1):14-22 PMID: 3510278
  135. Analysis and interpretation of response rates for anticancer drugs.
    Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1713-20 PMID: 526909
  136. Etoposide, cisplatin and doxorubicin in patients with small cell lung cancer: tumor response and long term survival.
    Eur J Cancer Clin Oncol. 1986 Jun;22(6):701-8 PMID: 3017722
  137. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    J Clin Oncol. 1989 Apr;7(4):450-6 PMID: 2538577
  138. Pharmacokinetics of high dose etoposide (VP 16-213).
    Eur J Cancer Clin Oncol. 1986 Oct;22(10):1149-55 PMID: 3643849
  139. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.
    Cancer Chemother Pharmacol. 1987;19(1):16-20 PMID: 3815721
  140. A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs.
    Cancer Chemother Rep 2. 1974 Dec;4(4):53-87 PMID: 4447935
  141. Chronic daily administration of oral etoposide--a phase I trial.
    J Clin Oncol. 1989 Mar;7(3):396-401 PMID: 2918334
  142. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide.
    J Natl Cancer Inst. 1985 Dec;75(6):1129-33 PMID: 3934448
  143. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
    Am J Clin Oncol. 1985 Oct;8(5):393-5 PMID: 4061373
  144. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
    J Clin Oncol. 1987 Sep;5(9):1356-63 PMID: 3476689
  145. Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.
    J Clin Oncol. 1983 May;1(5):295-301 PMID: 6686849
  146. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
    Eur J Cancer. 1975 Sep;11(9):639-47 PMID: 1220978
  147. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
    Cancer Res. 1987 Apr 1;47(7):1952-6 PMID: 3815383
  148. Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
    Am J Clin Oncol. 1985 Oct;8(5):401-5 PMID: 3904398
  149. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    J Clin Oncol. 1987 Aug;5(8):1191-8 PMID: 3114435
  150. VP16-213 as a single agent in advanced testicular tumors.
    Eur J Cancer. 1980 Sep;16(9):1193-7 PMID: 7227446
  151. Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
    J Clin Oncol. 1986 Mar;4(3):318-24 PMID: 3456425
  152. The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).
    Br J Cancer. 1983 May;47(5):613-9 PMID: 6189504
  153. A phase I trial of continuous infusion VP16-213 (etoposide).
    Cancer Chemother Pharmacol. 1982;7(2-3):157-60 PMID: 7083457
  154. VP 16-213 in acute myelogenous leukaemia.
    Postgrad Med J. 1976 Feb;52(604):66-70 PMID: 772645
  155. Use of liquid culture and cell cycle analysis to compare drug damage following in vitro treatment of normal human bone marrow cells with adriamycin, arabinosyl-cytosine, and etoposide.
    Exp Hematol. 1988 Nov;16(10):876-83 PMID: 3169155
  156. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.
    J Clin Oncol. 1987 Apr;5(4):556-61 PMID: 3559649
  157. Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.
    Eur J Cancer. 1973 Mar;9(3):215-21 PMID: 4787856
  158. High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.
    Cancer Chemother Pharmacol. 1985;15(3):303-6 PMID: 2996799
  159. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    J Clin Oncol. 1989 Sep;7(9):1327-32 PMID: 2671288
  160. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.
    J Neurooncol. 1984;2(2):133-9 PMID: 6481426
  161. Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213.
    Am J Clin Oncol. 1983 Jun;6(3):327-30 PMID: 6303106
  162. Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay.
    Jpn J Cancer Res. 1986 Mar;77(3):312-8 PMID: 3084421
  163. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Cancer Treat Rep. 1981 May-Jun;65(5-6):377-81 PMID: 7016323
  164. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
    J Clin Oncol. 1984 Apr;2(4):271-4 PMID: 6368760
  165. Further advances in the management of malignant teratomas of the testis and other sites.
    Lancet. 1983 Apr 30;1(8331):948-51 PMID: 6188011
  166. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer.
    Cancer Chemother Pharmacol. 1982;7(2-3):147-50 PMID: 7083455
  167. Interaction of etoposide and cisplatin in an in vitro tumor model.
    Cancer Treat Rep. 1987 Jul-Aug;71(7-8):673-9 PMID: 3607781
  168. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
    Cancer Treat Rep. 1987 Jun;71(6):661-2 PMID: 3034423
  169. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells.
    Biochemistry. 1976 Dec 14;15(25):5435-43 PMID: 999818
  170. High-dose etoposide for refractory malignancies: a phase I study.
    Cancer Treat Rep. 1984 Dec;68(12):1471-4 PMID: 6509453
  171. Combination vincristine and VP-16-213: evaluation of drug sequence.
    Cancer Biochem Biophys. 1986 Oct;8(4):265-75 PMID: 3802048
  172. A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.
    Cancer. 1975 Apr;35(4):1141-4 PMID: 163675
  173. A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia.
    Aust N Z J Med. 1986 Feb;16(1):48-51 PMID: 3458446
  174. Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
    Med Oncol Tumor Pharmacother. 1986;3(2):95-9 PMID: 3018396
  175. Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer.
    Cancer Invest. 1988;6(1):1-5 PMID: 2835127
  176. Pharmacokinetics of etoposide in gestochoriocarcinoma.
    Cancer Treat Rep. 1985 Jan;69(1):69-72 PMID: 2981622
  177. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
    Cancer. 1987 Mar 15;59(6):1072-82 PMID: 3028596
  178. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
    N Engl J Med. 1987 Jun 4;316(23):1435-40 PMID: 2437455
  179. Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside).
    Cancer. 1977 Aug;40(2):633-7 PMID: 196736
  180. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
    J Biol Chem. 1984 Nov 10;259(21):13560-6 PMID: 6092381
  181. Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.
    Cancer Chemother Pharmacol. 1987;19(2):172-4 PMID: 3032470
  182. Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16.
    FEBS Lett. 1988 Jan 25;227(2):240-4 PMID: 2828121
  183. Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.
    Cancer Chemother Pharmacol. 1987;19(3):250-2 PMID: 3581419
  184. The pharmacokinetics of high dose cyclophosphamide and high dose etoposide.
    Med Oncol Tumor Pharmacother. 1988;5(2):117-23 PMID: 2842552
  185. Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin.
    Int J Androl. 1987 Feb;10(1):311-7 PMID: 2438224
  186. EVA treatment for recurrent or unresponsive Hodgkin's disease.
    Cancer Chemother Pharmacol. 1986;18(1):51-3 PMID: 3757159
  187. Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin.
    Cancer Treat Rep. 1987 Jun;71(6):655-6 PMID: 2438041
  188. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.
    J Clin Oncol. 1985 May;3(5):666-71 PMID: 2582097
  189. Combined modalities of resistance in etoposide-resistant human KB cell lines.
    Cancer Res. 1988 Nov 1;48(21):5956-64 PMID: 2844393
  190. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma.
    Am J Clin Oncol. 1989 Feb;12(1):53-6 PMID: 2643295
  191. Chemotherapy of invasive carcinoma of the bladder.
    Aust N Z J Surg. 1985 Jun;55(3):249-52 PMID: 3863578
  192. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial.
    Cancer. 1989 Feb 15;63(4):638-42 PMID: 2536584
  193. Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents.
    NCI Monogr. 1987;(4):73-8 PMID: 2819735
  194. Three months treatment with chemotherapy and radiotherapy for small cell lung cancer.
    Br J Cancer. 1985 Sep;52(3):327-32 PMID: 2994703
  195. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.
    Ann Intern Med. 1987 Oct;107(4):451-8 PMID: 2820289
  196. VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas.
    Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1135-7 PMID: 7459900
  197. Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation.
    Cancer Treat Rep. 1987 Jul-Aug;71(7-8):759-61 PMID: 3038317
  198. Qualitative and quantitative aspects of intercalator-induced DNA strand breaks.
    Biochim Biophys Acta. 1979 Mar 28;562(1):41-50 PMID: 435499
  199. Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213.
    Acta Haematol. 1988;80(1):17-22 PMID: 3135688
  200. Cis-dichlorodiammineplatinum (II), VP 16-213, and prednisone (DVP regimen) in the treatment of pretreated advanced malignant lymphomas.
    Tumori. 1982 Dec 31;68(6):515-8 PMID: 6762740
  201. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.
    Cancer Chemother Pharmacol. 1982;7(2-3):175-7 PMID: 7083459
  202. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    J Clin Oncol. 1987 Dec;5(12):1880-9 PMID: 2824710
  203. Review of etoposide single-agent activity.
    Cancer Treat Rev. 1982 Jun;9 Suppl:21-30 PMID: 6751532
  204. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems.
    Mutagenesis. 1987 May;2(3):179-86 PMID: 3325741
  205. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV).
    Cancer Treat Rep. 1984 Nov;68(11):1325-9 PMID: 6388831
  206. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
    Cancer Res. 1984 Jan;44(1):379-82 PMID: 6690051
  207. Etoposide, methotrexate, and bleomycin in drug-resistant gestational trophoblastic disease.
    Gynecol Oncol. 1986 May;24(1):51-7 PMID: 2422094
  208. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
    Gynecol Oncol. 1985 Oct;22(2):162-6 PMID: 4054715
  209. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
    Am J Clin Oncol. 1982 Oct;5(5):515-9 PMID: 6758569
  210. Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia.
    Cancer Chemother Pharmacol. 1982;7(2-3):161-7 PMID: 6177437
  211. Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas.
    Am J Clin Oncol. 1988 Apr;11(2):172-3 PMID: 3282425
  212. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
    Exp Hematol. 1986 Aug;14(7):626-35 PMID: 3525202
  213. Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study.
    Cancer Treat Rep. 1987 Sep;71(9):869-70 PMID: 3621221
  214. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma.
    J Clin Oncol. 1988 Jan;6(1):44-50 PMID: 3335892
  215. Cisplatin, etoposide, and radiotherapy in regional inoperable squamous cell carcinoma of the bronchus.
    Semin Oncol. 1985 Mar;12(1 Suppl 2):14-6 PMID: 4038819
  216. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
    Cancer Treat Rep. 1984 Sep;68(9):1079-84 PMID: 6090014
  217. Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells.
    Biochim Biophys Acta. 1984 Oct 5;783(1):74-9 PMID: 6477925
  218. Unchanged pharmacokinetics of VP-16-213 (etoposide, NSC 141540) during concomitant administration of doxorubicin and cyclophosphamide.
    Eur J Cancer Clin Oncol. 1987 Jun;23(6):807-11 PMID: 2820744
  219. Cisplatin plus vindesine versus cisplatin plus VP16 versus doxorubicin plus cytoxan in non-small-cell carcinoma of the lung. A randomized study.
    Tumori. 1986 Aug 31;72(4):417-25 PMID: 3020754
  220. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984).
    Br J Obstet Gynaecol. 1986 Jan;93(1):63-9 PMID: 3002420
  221. Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer.
    Cancer Chemother Pharmacol. 1990;25(5):367-70 PMID: 2155064
  222. Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancer.
    Cancer. 1985 Sep 15;56(6):1332-6 PMID: 2992736
  223. Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy.
    Cancer Treat Rev. 1983 Sep;10 Suppl A:137-43 PMID: 6627240
  224. Phase II study with etoposide in previously untreated advanced breast cancer.
    Cancer Chemother Pharmacol. 1989;24(4):261-3 PMID: 2752508
  225. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
    Cancer Treat Rep. 1985 Jan;69(1):127-8 PMID: 2981617
  226. Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma.
    J Clin Oncol. 1989 Jul;7(7):900-3 PMID: 2472471
  227. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
    Am J Clin Oncol. 1984 Oct;7(5):471-3 PMID: 6594926
  228. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules.
    Cancer Res. 1987 Nov 15;47(22):5835-40 PMID: 3117357
  229. VP16-213 and cyclophosphamide in advanced breast cancer. A phase II study.
    Cancer Chemother Pharmacol. 1983;10(3):154-7 PMID: 6861258
  230. VP-16-213 salvage therapy for refractory germinal neoplasms.
    Cancer. 1980 Nov 15;46(10):2154-8 PMID: 6159062
  231. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
    J Clin Oncol. 1987 Jul;5(7):1007-14 PMID: 3598607
  232. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Cancer Treat Rep. 1981 Mar-Apr;65(3-4):329-30 PMID: 7016320
  233. Etoposide-induced DNA cleavage in human leukemia cells.
    Cancer Chemother Pharmacol. 1987;20(2):162-8 PMID: 2822274
  234. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    J Clin Oncol. 1988 Sep;6(9):1411-6 PMID: 2458439
  235. The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
    Semin Oncol. 1985 Mar;12(1 Suppl 2):2-6 PMID: 2983433
  236. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.
    J Clin Oncol. 1985 Feb;3(2):176-83 PMID: 2981982
  237. Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma.
    Cancer. 1982 Aug 15;50(4):652-8 PMID: 6284335
  238. A phase III of cisplatinum versus cisplatinum-etoposide for previously untreated squamous cell carcinoma of the head and neck.
    Anticancer Res. 1987 May-Jun;7(3 Pt B):455-8 PMID: 3307601
  239. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Ann Intern Med. 1986 Feb;104(2):163-8 PMID: 3511811
  240. Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors.
    Am J Med. 1985 Mar;78(3):423-8 PMID: 2983547
  241. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.
    Cancer Chemother Pharmacol. 1985;15(1):66-71 PMID: 4039984
  242. Inhibition of DNA ligase from human thymocytes and normal or leukemic lymphocytes by antileukemic drugs.
    Cancer Res. 1985 May;45(5):2177-83 PMID: 3986768
  243. Chemotherapy of advanced non-small cell lung cancer with the use of cis-platinum and VP 16-213.
    Southeast Asian J Trop Med Public Health. 1985 Dec;16(4):641-5 PMID: 3835710
  244. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.
    Br J Cancer. 1989 Apr;59(4):578-83 PMID: 2540788
  245. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
    Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2089-92 PMID: 526942
  246. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.
    J Clin Oncol. 1989 Sep;7(9):1318-26 PMID: 2769330
  247. DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.
    Cancer Res. 1983 Jan;43(1):120-4 PMID: 6847761
  248. Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.
    Cancer Res. 1984 Jul;44(7):3109-13 PMID: 6539169
  249. Synergistic antitumor activity of vincristine and VP-16-213.
    Cancer Chemother Pharmacol. 1984;13(3):176-80 PMID: 6488438
  250. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.
    J Clin Oncol. 1989 Sep;7(9):1310-7 PMID: 2671287
  251. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
    Cancer Treat Rep. 1987 Feb;71(2):187-9 PMID: 3802114
  252. Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer.
    Cancer. 1985 Nov 15;56(10):2399-403 PMID: 2412681
  253. The effect of dose on the bioavailability of oral etoposide.
    Cancer Chemother Pharmacol. 1986;16(2):178-81 PMID: 3004772
  254. Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy.
    Cancer Chemother Pharmacol. 1982;7(2-3):179-80 PMID: 6282480
  255. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
    Cancer Res. 1986 May;46(5):2566-71 PMID: 3697995
  256. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
    J Clin Oncol. 1986 Jan;4(1):4-13 PMID: 3510281
  257. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro.
    Cancer Res. 1984 Mar;44(3):984-9 PMID: 6692420
  258. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro.
    Cancer Res. 1985 Apr;45(4):1651-6 PMID: 3978633
  259. VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
    J Clin Oncol. 1985 Nov;3(11):1471-7 PMID: 2997406
  260. High-dose cis-platinum combination chemotherapy in advanced nonseminomatous malignant germ cell tumours with emphasis on nephrotoxicity.
    Cancer Chemother Pharmacol. 1986;18(1):74-7 PMID: 2428537
  261. Phase II trial of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group.
    Cancer Treat Rep. 1987 May;71(5):525-7 PMID: 3567976
  262. Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
    Eur J Cancer Clin Oncol. 1987 Nov;23(11):1673-8 PMID: 3480803
  263. Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study.
    Cancer. 1986 Sep 1;58(5):1018-9 PMID: 3015372
  264. Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide.
    Oncology. 1985;42(4):224-8 PMID: 4040233
  265. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.
    Cancer Treat Rep. 1976 Nov;60(11):1681-2 PMID: 1021239
  266. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
    Cancer Treat Rep. 1976 Jul;60(7):949-51 PMID: 64298
  267. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
    J Clin Oncol. 1986 May;4(5):702-9 PMID: 3701389
  268. Results of MIME salvage regimen for recurrent or refractory lymphoma.
    J Clin Oncol. 1987 Mar;5(3):407-12 PMID: 3819806
  269. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Eur J Cancer Clin Oncol. 1986 Jul;22(7):761-4 PMID: 3770033
  270. Effects of the antitumor drug VP16 (etoposide) on the archaebacterial Halobacterium GRB 1.7 kb plasmid in vivo.
    Nucleic Acids Res. 1987 Oct 26;15(20):8217-34 PMID: 3671082
  271. Hypersensitivity reactions induced by etoposide.
    Cancer Treat Rep. 1984 Jul-Aug;68(7-8):959-61 PMID: 6744346
  272. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance.
    Cancer Chemother Pharmacol. 1986;16(1):50-4 PMID: 3455667
  273. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.
    J Clin Oncol. 1987 Jun;5(6):941-50 PMID: 3585448
  274. Etoposide for therapy-resistant testicular tumors.
    Cancer Treat Rev. 1982 Jun;9 Suppl:73-8 PMID: 7127337
  275. Phase II study of oral VP-16-213 in small cell lung cancer.
    Cancer. 1987 Dec 15;60(12):2882-5 PMID: 2824017
  276. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.
    J Clin Oncol. 1985 Jan;3(1):65-71 PMID: 2981293
  277. cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.
    Cancer Chemother Pharmacol. 1983;11(1):35-7 PMID: 6683999
  278. Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.
    Cancer Chemother Pharmacol. 1984;12(1):64-5 PMID: 6690078
  279. Treatment of acute non lymphocytic leukemia. Results of a prospective trial of daunorubicin, arabinosylcytosine and 6-thioguanine (DAT) versus DAT plus vindesine and etoposide.
    Haematologica. 1987 Sep-Oct;72(5):431-7 PMID: 3121465
  280. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.
    J Cell Biol. 1975 Sep;66(3):521-30 PMID: 1057547
  281. Preclinical assessment of purging with VP-16-213: key role for long-term marrow cultures.
    Blood. 1987 Jan;69(1):65-71 PMID: 3790729
  282. Etoposide as single agent and in combination with cis-platinum for malignant lymphomas.
    Cancer Treat Rev. 1982 Jun;9 Suppl:39-43 PMID: 6889920
  283. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease.
    Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6 PMID: 2420012
  284. Chemotherapy consisting of epirubicin, cisplatin, and etoposide followed by irradiation in stage III non-small cell lung cancer and chemotherapy alone in stage IV non-small cell lung cancer.
    Oncology. 1988;45(6):413-6 PMID: 2847098
  285. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    J Clin Oncol. 1988 Mar;6(3):451-6 PMID: 2832549
  286. Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC).
    Cancer Chemother Pharmacol. 1982;7(2-3):205-7 PMID: 7083460
  287. High-dose cisplatin and VP-16 with bleomycin, in the management of advanced metastatic germ cell tumors.
    Eur J Cancer Clin Oncol. 1986 Apr;22(4):477-85 PMID: 2426115
  288. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia.
    Acta Pathol Microbiol Scand A. 1973 Sep;81(5):715-24 PMID: 4771975
  289. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.
    J Clin Oncol. 1987 Oct;5(10):1574-8 PMID: 2821197
  290. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
    Cancer Res. 1988 Sep 15;48(18):5096-100 PMID: 2842045
  291. VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study.
    Med Pediatr Oncol. 1988;16(5):312-9 PMID: 3054453
  292. Intensive chemotherapy including cisplatin with or without etoposide for children with soft-tissue sarcomas.
    Med Pediatr Oncol. 1987;15(2):51-7 PMID: 3587117
  293. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
    Cancer Res. 1989 Jun 15;49(12):3178-83 PMID: 2720673
  294. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.
    J Clin Oncol. 1984 Mar;2(3):215-20 PMID: 6321690
  295. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
    Cancer. 1980 Jan 15;45(2):232-5 PMID: 6985831
  296. Model studies of etoposide resistance.
    Cancer Treat Rev. 1982 Jun;9 Suppl:15-20 PMID: 6957266
  297. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.
    Cancer Chemother Pharmacol. 1987;20(1):59-66 PMID: 3621455
  298. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
    Cancer Treat Rep. 1981 May-Jun;65(5-6):443-5 PMID: 7237465
  299. Altered protein binding of etoposide in patients with cancer.
    Clin Pharmacol Ther. 1989 Jan;45(1):49-55 PMID: 2910637
  300. A phase II study of oral etoposide in elderly patients with small cell lung cancer.
    Thorax. 1989 Aug;44(8):631-3 PMID: 2477908
  301. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.
    Cancer Treat Rep. 1985 Nov;69(11):1279-82 PMID: 3004725
  302. The effect of etoposide on human CFU-GM.
    Br J Cancer. 1985 Oct;52(4):613-7 PMID: 4063137
  303. Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.
    Cancer Chemother Pharmacol. 1982;7(2-3):223-5 PMID: 7083463
  304. Pharmacokinetics of high-dose etoposide.
    Clin Pharmacol Ther. 1988 May;43(5):561-4 PMID: 3284691
  305. Acute vasomotor response--a reaction to etoposide.
    J Clin Oncol. 1988 Jul;6(7):1204-5 PMID: 3079542
  306. Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8).
    Br J Cancer. 1985 Jul;52(1):7-13 PMID: 3893507
  307. Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party.
    Cancer Treat Rep. 1983 Jul-Aug;67(7-8):727-30 PMID: 6347374
  308. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
    Cancer Treat Rep. 1979 Mar;63(3):513-5 PMID: 371804
  309. Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy.
    J Clin Oncol. 1983 Aug;1(8):483-8 PMID: 6321685
  310. High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy.
    J Clin Oncol. 1986 Feb;4(2):194-9 PMID: 2418168
  311. The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma.
    Cancer Chemother Pharmacol. 1982;7(2-3):211-4 PMID: 7083462
  312. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
    J Clin Oncol. 1986 Apr;4(4):528-36 PMID: 3633952
  313. Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro.
    Cancer Res. 1974 Aug;34(8):1788-93 PMID: 4210356
  314. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    J Clin Oncol. 1988 Feb;6(2):213-7 PMID: 3422260
  315. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
    Semin Oncol. 1985 Mar;12(1 Suppl 2):21-2 PMID: 3883504
  316. Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung.
    Semin Oncol. 1986 Sep;13(3 Suppl 3):54-62 PMID: 3020702
  317. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma.
    Gynecol Oncol. 1987 Jul;27(3):350-6 PMID: 3305186
  318. Pharmacokinetics of VP16-213 given by different administration methods.
    Cancer Chemother Pharmacol. 1982;7(2-3):141-5 PMID: 7083454
  319. Single-dose etoposide in combination with vincristine and doxorubicin in the treatment of small-cell lung cancer (SCLC).
    Semin Oncol. 1985 Mar;12(1 Suppl 2):45-7 PMID: 2983435
  320. Cyclophosphamide, etoposide, and infusion cisplatin in refractory small cell lung cancer. A preliminary report.
    Am J Clin Oncol. 1987 Feb;10(1):33-5 PMID: 3030092
  321. Combination cyclophosphamide, Adriamycin, and vincristine rapidly alternating with combination cisplatin and VP-16 in treatment of small cell lung cancer.
    Am J Med. 1985 Sep;79(3):303-8 PMID: 2994472
  322. Phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung.
    Cancer Treat Rep. 1987 Jun;71(6):575-80 PMID: 3034422
  323. Use of oral VP16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease.
    Am J Obstet Gynecol. 1984 Dec 15;150(8):924-7 PMID: 6095666
  324. Etoposide pharmacokinetics in patients with normal and abnormal organ function.
    J Clin Oncol. 1986 Nov;4(11):1690-5 PMID: 3772420
  325. Etoposide (VP-16-213). Current status of an active anticancer drug.
    N Engl J Med. 1985 Mar 14;312(11):692-700 PMID: 2983208
  326. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
    Cancer Res. 1982 Nov;42(11):4719-25 PMID: 6889912
  327. Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide.
    Cancer Chemother Pharmacol. 1989;23(6):373-6 PMID: 2653659
  328. Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer.
    Cancer. 1985 Nov 15;56(10):2411-5 PMID: 2412683
  329. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
    Eur J Respir Dis. 1985 Oct;67(4):294-300 PMID: 3000808
  330. Cyclic alternating chemotherapy for small cell carcinoma of the lung.
    Cancer Treat Rep. 1985 Nov;69(11):1241-2 PMID: 3004724
  331. Phase II evaluation of diglycoaldehyde, VP-16-213, and the combination of methyl-CCNU and beta-2'-deoxythioguanosine in previously treated patients with colorectal cancer: an Eastern Cooperative Oncology Group study (EST-1275).
    Cancer Treat Rep. 1979 Aug;63(8):1355-7 PMID: 476709
  332. Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen.
    Cancer Chemother Pharmacol. 1985;14(3):258-61 PMID: 4039635
  333. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma.
    J Clin Oncol. 1986 Dec;4(12):1780-6 PMID: 3023556
  334. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.
    J Clin Oncol. 1985 Nov;3(11):1478-85 PMID: 2414409
  335. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.
    Oncology. 1980;37(3):149-51 PMID: 7360486
  336. A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer.
    Semin Oncol. 1986 Sep;13(3 Suppl 3):97-103 PMID: 3020707
Article Info
Journal
Drugs
Abbr.
Drugs
ISSN
0012-6667
DOI
10.2165/00003495-199039030-00008
Published
1990-03-00
Pages
438-90
Language
English
Region
New Zealand
NLM ID
7600076
Subset
IM
External Links
PubMed source DOI: 10.2165/00003495-199039030-00008 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2